Overview

A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer

Status:
Unknown status

Trial end date:
2017-06-01

Target enrollment:

Participant gender:

Summary

A study of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with Gastric Cancer.The purpose of this study is to compare the activity of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with gastric carcinoma by estimating progression free survival (PFS) in each treatment arm.

Phase:

Phase 2

Details

Lead Sponsor:

Hebei Tumor Hospital

Treatments:

Docetaxel
Raltitrexed